Loading
Latest filing published 17 Aug 2022 for Turning Point Therapeutics, Inc., €2.7M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Steve M. Sabus, listed as senior executive, appears in our data through filings on Turning Point Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 2 filings, for trades running from 31 May 2022 to 17 August 2022.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 17 August 2022 with a transaction (€2.7M) in Turning Point Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations